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METHODS: This study used administrative claims data
to identify continuously enrolled patients using insulin
between 1/1/98 and 12/31/99. During a six-month iden-
tiﬁcation period, patients receiving one or more prescrip-
tions for lispro were categorized as lispro patients.
Non-lispro patients were then matched to lispro patients
using a Propensity Score (PS) derived from baseline char-
acteristics. The PS model included variables such as age,
gender, comorbidities, oral hypoglycemic use, dominant
physician specialty, health plan location and baseline
costs. After 1 :1 matching, 12 months of follow-up cost
and utilization data were then compared using
unmatched t-tests.
RESULTS: Of 11,443 patients, 3,341 (29.2%) had at
least one prescription for lispro insulin, while the remain-
ing 8,102 (70.8%) had at least one regular (non-lispro)
insulin prescription. At baseline, lispro patients tended to
be younger, were more often Type 1 with a history of
insulin use, had fewer comorbidities, visited endocrinol-
ogists over family practice physicians and had lower total
costs. PS balancing assured that only the 1,832 most
appropriate patients of each type were then used in out-
comes comparisons. Lispro patients had signiﬁcantly
higher average ofﬁce visits (p = 0.0022) and pharmacy
prescriptions (p = 0.0165) but lower inpatient hospital
visits (p = 0.0028) compared to non-lispro patients. Cost
results were similar with lispro insulin patients having sig-
niﬁcantly higher average ofﬁce visit costs (p = 0.0237) and
pharmacy costs (p < 0.0001) but lower inpatient hospital
costs (p = 0.0227). Total costs were not signiﬁcantly 
different (p = 0.5266).
CONCLUSIONS: Lispro insulin and non-lispro regular
insulin patients did not incur signiﬁcantly different total
costs. While lispro patients had higher pharmacy and
ofﬁce visit costs, they did not incur higher total medical
costs. More intensive ambulatory care in such chronic
disease patients does not appear to be associated with
higher overall medical costs.
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OBJECTIVES: To determine the relationship of demo-
graphics, severity of illness and quality of care measures
with general health perception (GHP) and patient satis-
faction (PS) levels among managed care diabetes patients.
METHODS: The sample included 300 adult diabetes
patients enrolled in an IPA-model HMO. All data were
collected through surveys and medical claims. Survey data
from July 1999 were merged with medical and pharmacy
claims data from July 1998 through June 1999. Our
analysis consisted of two multiple regression models with
GHP (100 point transformed scale, higher score = better
health) and PS (9 point scale, higher score = greater sat-
isfaction) being the dependent variables, respectively. Pre-
dictor variables in both models included: demographics
(age, gender, education, income), severity of illness
(insulin use, duration of diabetes), number of comorbidi-
ties, receipt of foot and eye exams, diabetes education,
lipid tests, microalbumin tests, frequency of self-
monitoring of blood glucose, and the frequency of tests
for HbA1c and blood glucose.
RESULTS: Mean (SD) for GHP and PS scores were 49.8
(25.0) and 7.8 (1.8), respectively. The R2 for model 1
(GHP) and model 2 (PS) were 0.20 and 0.10, respectively.
Signiﬁcant predictors (p < 0.05) of GHP included comor-
bidities (beta = -0.11), income (beta = 0.26), and HbA1c
tests (beta = 0.19). Thus, higher GHP was associated with
having fewer comorbidities, higher income and more fre-
quent testing of HbA1c in the prior year. Signiﬁcant pre-
dictors of PS included comorbidities (beta = -0.15), foot
exams (beta = 0.16), and diabetes education (beta = 0.16).
Thus, higher satisfaction was associated with fewer
comorbidities, receipt of a foot exam from any healthcare
provider, and participation in a diabetes education
program.
CONCLUSION: When controlling for demographics,
comorbidities and severity of illness, those patients who
received more frequent HbA1c monitoring reported
higher self-rated health, and patients who received foot
exams and diabetes education were more satisﬁed with
the care they received for diabetes.
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OBJECTIVES: New oral antihyperglycemic drugs
(OADs) have been introduced in recent years, and dia-
betes treatment guidelines are increasingly suggesting that
insulin be used for type-2 diabetes only when other ther-
apies are ineffective. This study evaluates the resulting
impacts on trends in insulin mono and combination 
therapies for type-2 diabetic patients from 1997–2000.
METHODS: Commercially insured patients who had one
or more diabetes diagnoses or drugs are selected from
over 3 million employees, retirees, and dependents in each
of the years 1997–2000 of The MEDSTAT Group Mar-
ketScan database. Patients likely to have type-1 diabetes
are identiﬁed and removed from the database. Descrip-
tive analyses compare the percentages of type-2 diabetes
patients treated with insulin monotherapy and speciﬁc
combination therapies in each of the four years. Statisti-
